New advances in the fight against a range of cancers have been revealed at the annual meeting of the American Society of Clinical Oncology (Asco), which wrapped up in Chicago on Tuesday.
Here are some of the announcements that have most excited experts in relation to this disease, which is the second-leading cause of deaths worldwide.
One of the trial results that caused a stir in Chicago has raised hopes for a new weapon against lung cancer, the deadliest of all cancers.
The treatment osimertinib was shown to halve the risk of death from a certain type of lung cancer when taken daily after surgery to remove the tumour.
Developed by the pharmaceutical group AstraZeneca, the daily pill targets patients with non-small cell cancer – by far the most common type – as well as a mutation of their epidermal growth factor receptor, or EGFR.
Iris Pauporte, head of research at France’s League Against Cancer, told AFP the advance was a “big ray of hope” for this type of cancer, for which progress has been slow.
Muriel Dahan, head of research at Unicancer, said if the results are confirmed, it “should change” common practice in treating this kind of lung cancer.
Systematic testing for the EGFR mutation would also become necessary for lung cancer patients, she added.
Another treatment, called vorasidenib, was found to significantly prolong the progression-free survival of patients with brain tumour glioma, according to clinical trial results.
The daily pill, developed by French pharma firm Servier, aims to block an enzyme responsible for the progression of some brain cancers, which have been particularly difficult to treat.
Patrick Therasse, Servier’s vice-president of oncology research, told AFP that there “have been few therapeutic advances for brain tumours over the last 20 years”.
“Thanks to our targeted treatment, patients avoided cancer progression for 27.7 months, compared with 11.1 months” for those taking a placebo, he added.
Fabrice Andre, head of research at France’s Gustave Roussy cancer centre, said “precision medicine opens a door for a disease for which there was nothing until now”.
“It means that science can unblock situations that were catastrophic,” he told AFP.
Unicancer’s Dahan said it was important to “remain cautious”, but added that “this could become the new therapeutic standard – depending on further trials”.
Preliminary trial results also released in Chicago indicated the drug ribociclib reduced the risk of breast cancer recurrence by 25% for a large group of early-stage survivors.
The drug, developed by Swiss pharmaceutical maker Novartis, is already widely approved around the world. It was tested in combination with hormonal therapy.
Aco expert Rita Nanda said it was a “very important and practice-changing clinical trial”.
There was also good news for patients with early-stage cervical cancer with a low risk of progression.
There was no greater risk of the cancer returning for patients who get a simple hysterectomy, in which the uterus and cervix are removed, than a radical hysterectomy, in which the uppermost part of the vagina is also removed, according to phase-three trials.
League Against Cancer’s Pauporte pointed out that this shows ‘it’s not just progress involving drugs that was important”.
A trial also presented at Asco showed that taking the antibody treatment mirvetuximab soravtansine significantly improved the survival rate of patients with ovarian cancer, a particularly deadly form of the disease.
Asco expert Merry Jennifer Markham said the treatment “demonstrates progress and offers hope for these patients”.
Study results released in Chicago indicated that patients with locally advanced rectal cancer could receive chemotherapy without getting radiation therapy before undergoing surgery.
This would spare patients from the brutal side effects of radiation.
Vaccines that treat existing cancer have long been a goal of the medical community. Preliminary studies announced at the Asco meeting involved vaccines targeting lung cancer, head and neck cancers, brain tumour glioblastoma, and the cancer-causing HPV virus.
Christophe Le Tourneau, an oncologist at France’s Curie Institute, which presented a study about a vaccine for a certain form of HPV, said there has been “significant technological progress” in the area recently.
“We talk about therapeutic vaccines more and more, and there are more and more trials in progress,” he said.